NEW YORK (GenomeWeb) – Predicine announced today that it has closed a $13.5 million Series A round of financing.
Chinese venture capital firms Sangel Capital, Rongsheng Investment, and Highlight Capital participated in the round.
Predicine said it will use the funding to advance the commercialization of its proprietary liquid biopsy technology, as well as its use in clinical trials, treatment selection, and cancer screening. The firm also intends to expand its cancer biomarker pipeline.